Trade Sarepta Therapeutics, Inc. - SRPT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.28 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 116.46 |
| Open | 115.99 |
| 1-Year Change | 0.61% |
| Day's Range | 115.6 - 118.14 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 117.81 | 0.56 | 0.48% | 117.25 | 118.32 | 114.95 |
| Jan 16, 2025 | 116.46 | -2.82 | -2.36% | 119.28 | 119.28 | 114.25 |
| Jan 15, 2025 | 118.62 | -1.08 | -0.90% | 119.70 | 122.76 | 118.18 |
| Jan 14, 2025 | 118.70 | -0.50 | -0.42% | 119.20 | 123.06 | 118.03 |
| Jan 13, 2025 | 118.31 | -5.14 | -4.16% | 123.45 | 127.02 | 115.96 |
| Jan 10, 2025 | 124.70 | 0.44 | 0.35% | 124.26 | 127.96 | 123.27 |
| Jan 8, 2025 | 125.95 | 2.49 | 2.02% | 123.46 | 127.42 | 122.11 |
| Jan 7, 2025 | 123.70 | -4.25 | -3.32% | 127.95 | 129.70 | 123.25 |
| Jan 6, 2025 | 127.83 | 1.88 | 1.49% | 125.95 | 128.62 | 125.35 |
| Jan 3, 2025 | 125.82 | 1.61 | 1.30% | 124.21 | 127.10 | 123.54 |
| Jan 2, 2025 | 123.83 | 2.73 | 2.25% | 121.10 | 126.56 | 121.10 |
| Dec 31, 2024 | 121.02 | 0.52 | 0.43% | 120.50 | 122.41 | 119.78 |
| Dec 30, 2024 | 120.81 | 1.82 | 1.53% | 118.99 | 121.44 | 118.63 |
| Dec 27, 2024 | 121.28 | 0.68 | 0.56% | 120.60 | 122.84 | 120.30 |
| Dec 26, 2024 | 123.05 | 2.75 | 2.29% | 120.30 | 123.43 | 120.30 |
| Dec 24, 2024 | 121.83 | 2.88 | 2.42% | 118.95 | 121.91 | 118.95 |
| Dec 23, 2024 | 120.13 | 1.91 | 1.62% | 118.22 | 120.81 | 117.01 |
| Dec 20, 2024 | 118.89 | -0.66 | -0.55% | 119.55 | 120.82 | 118.07 |
| Dec 19, 2024 | 119.11 | -1.32 | -1.10% | 120.43 | 121.45 | 117.68 |
| Dec 18, 2024 | 120.12 | -4.83 | -3.87% | 124.95 | 124.96 | 119.56 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Sarepta Company profile
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com